サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739157

HIV注射の世界市場

HIV Injections

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
HIV注射の世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

HIV注射の世界市場は2030年までに30億米ドルに到達

2024年に11億米ドルと推定されるHIV注射の世界市場は、2024年から2030年にかけてCAGR 17.6%で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである病院薬局流通チャネルは、CAGR 19.2%を記録し、分析期間終了時には18億米ドルに達すると予測されます。ドラッグストア・小売薬局流通チャネルは、分析期間中CAGR 15.1％で成長すると推定されます。

米国市場は推定3億1,160万米ドル、中国はCAGR23.4％で成長予測

米国のHIV注射市場は、2024年に3億1,160万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR23.4%で推移し、2030年には6億7,910万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.9%と15.9%と予測されています。欧州では、ドイツがCAGR約14.1%で成長すると予測されています。

世界のHIV注射市場- 主要動向と促進要因のまとめ

なぜ長時間作用型HIV注射が治療アドヒアランスとアウトカムを再構築するのか？

HIV注射、特に長時間作用型注射抗レトロウイルス療法（ART）は、服薬アドヒアランスを改善し、錠剤の負担を軽減し、毎日の内服に関連するスティグマを軽減することで、HIV治療のパラダイムを変革しています。これらの注射製剤は隔月または毎月投与され、ウイルス抑制が安定している患者にとって、経口ARTレジメンに代わる臨床的に証明された選択肢として登場しました。注射によるARTは、利便性が高く、自由度が高いため、HIVとともに生きる人々の治療継続と生活の質全体を改善する可能性があります。

現在、最も有力な選択肢は長時間作用型の注射剤であるカボテグラビルとリルピビリンの併用療法であり、さらに多くの候補が後期開発段階にあります。これらのレジメンは、十分な治療を受けていない人々、アドヒアランスに問題のある人々、ヘルスケアへのアクセスが不規則な環境において、特に大きな効果を発揮します。治療だけでなく、長時間作用型の注射による曝露前予防薬（PrEP）の選択肢もまた、リスクのある集団に有望であり、経口PrEPと比較して、より長い防御間隔を提供し、毎日のアドヒアランス要件を軽減します。

製剤とデリバリーにおける革新は、HIV注射の効果をどのように高めているか？

製剤、デポ技術、筋肉内デリバリーメカニズムの進歩により、HIV注射はより安全で、より効果的で、投与しやすくなっています。長時間作用型のナノ懸濁液や徐放性マイクロスフェア技術により、全身的な変動を最小限に抑えた持続的な薬物放出が可能になりました。これらの製剤は治療血漿中濃度を長期間維持するため、有効性が向上するだけでなく、投与漏れによる耐性発現のリスクも低減します。

臨床試験や実臨床試験では、代替投与頻度、注射部位の忍容性、自己投与の可能性などが評価され続けています。自動注射器技術、無針投与、マルチメカニズムART化合物との併用注射などが、利便性をさらに高めるために検討されています。一方、ファーマコビジランスと世界・アクセス・イニシアチブは、特にサハラ以南のアフリカのような、物流とコストの障壁が依然として大きい高負担地域において、公平な流通を確保するために取り組んでいます。

注射用HIV治療薬の需要を牽引している市場と人口は？

北米と西欧は現在、強力な医療インフラ、規制当局の承認、有利な償還モデルにより、注射用HIV治療薬の採用をリードしています。米国では、長時間作用型の注射用ARTがすでに臨床HIV治療に組み込まれており、EUも急速にこれに追随しています。アフリカや東南アジアを含む世界の南半球は、HIV有病率が高く、簡便な投与レジメンが公衆衛生に影響を与える可能性があることから、長期的に最も重要な機会となります。

MSM（男性と性交渉を持つ男性）、セックスワーカー、トランスジェンダーなどの高リスク集団は、注射型PrEPプログラムの主なターゲットです。治療においては、アドヒアランスが困難な患者、精神衛生上の課題がある患者、不安定な生活環境にある患者が、長時間作用型の選択肢の重要な受益者です。NGO、公衆衛生機関、および国際的なドナー・プログラムは、HIV流行を終わらせるための世界のUNAIDS目標の一環として、HIV予防・治療プロトコルに注射療法を含めるようになってきています。

HIV注射市場の成長はいくつかの要因によって牽引されている...

HIV注射市場の成長は、長時間作用型製剤における医薬技術革新、アドヒアランスに配慮した治療薬に対する需要の増加、ARTアクセス改善のための世界の取り組みなど、いくつかの要因によって牽引されています。技術的には、徐放性注射剤プラットフォームやナノ粒子送達システムにより、治療範囲の拡大や投与回数の減少が可能になっています。規制当局の承認と臨床ガイドラインの更新が高所得国での市場参入を後押しする一方、ドナー主導のプログラムが低所得地域での試験的展開を加速させています。

最終用途の観点からは、高リスク集団におけるPrEPの需要の高まり、非付着患者における治療成績の改善、簡便なモニタリングに対するヘルスケア提供者の嗜好が、注射剤の採用を後押ししています。スティグマ、アドヒアランス疲労、世界のアクセスの課題が続く中、HIV注射は従来の経口レジメンに代わる魅力的な選択肢を提供し、HIVに罹患している、または罹患しやすいすべての人々の生活の質（QOL）とウイルス抑制の成果を向上させる世界の取り組みに合致するものです。

セグメント

流通チャネル（病院薬局、ドラッグストア・小売薬局、その他の流通チャネル）

調査対象企業の例（注目の41社）

  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson（Janssen）
  • Lupin Limited
  • Mylan N.V.（Viatris Inc.）
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz（a Novartis division）
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • ViiV Healthcare
  • Zydus Lifesciences Limited

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33930

Global HIV Injections Market to Reach US$3.0 Billion by 2030

The global market for HIV Injections estimated at US$1.1 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. Hospital Pharmacy Distribution Channel, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Drugs Stores & Retail Pharmacies Distribution Channel segment is estimated at 15.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$311.6 Million While China is Forecast to Grow at 23.4% CAGR

The HIV Injections market in the U.S. is estimated at US$311.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$679.1 Million by the year 2030 trailing a CAGR of 23.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 15.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.

Global HIV Injections Market - Key Trends & Drivers Summarized

Why Are Long-Acting HIV Injections Reshaping Treatment Adherence and Outcomes?

HIV injections, particularly long-acting injectable antiretroviral therapies (ART), are transforming HIV treatment paradigms by improving adherence, reducing pill burden, and mitigating stigma associated with daily oral medication. These injectable formulations-administered bi-monthly or monthly-have emerged as a clinically proven alternative to oral ART regimens for individuals with stable viral suppression. The convenience and discretion associated with injectable ART have the potential to improve treatment retention and overall quality of life for people living with HIV.

Currently, the most prominent options include long-acting injectable cabotegravir and rilpivirine combinations, with more candidates in late-stage development. These regimens are especially impactful in underserved populations, individuals with adherence challenges, and settings where healthcare access is irregular. Beyond treatment, long-acting injectable pre-exposure prophylaxis (PrEP) options are also showing strong promise for at-risk populations, offering longer protection intervals and reducing the daily adherence requirement compared to oral PrEP.

How Is Innovation in Formulation and Delivery Enhancing the Impact of HIV Injections?

Advances in drug formulation, depot technologies, and intramuscular delivery mechanisms are making HIV injections safer, more effective, and easier to administer. Long-acting nanosuspensions and extended-release microsphere technologies allow for sustained drug release with minimal systemic fluctuation. These formulations maintain therapeutic plasma concentrations for extended periods, which not only improves efficacy but also reduces the risk of resistance development due to missed doses.

Clinical trials and real-world studies continue to evaluate alternate dosing frequencies, injection site tolerability, and self-administration feasibility. Auto-injector technologies, needleless delivery, and combination injections with multi-mechanism ART compounds are being explored to further enhance convenience. Meanwhile, pharmacovigilance and global access initiatives are working to ensure equitable distribution, especially in high-burden regions like sub-Saharan Africa where logistical and cost barriers remain significant.

Which Markets and Populations Are Driving Demand for Injectable HIV Treatments?

North America and Western Europe are currently leading the adoption of injectable HIV therapies due to strong healthcare infrastructure, regulatory approvals, and favorable reimbursement models. In the U.S., long-acting injectable ART is already being integrated into clinical HIV care, while the EU is rapidly following suit. The global South, including Africa and Southeast Asia, represents the most significant long-term opportunity, given the high HIV prevalence and the potential public health impact of simplified dosing regimens.

High-risk populations such as MSM (men who have sex with men), sex workers, and transgender individuals are primary targets for injectable PrEP programs. For treatment, patients with adherence difficulties, mental health challenges, or unstable living conditions are key beneficiaries of long-acting options. NGOs, public health agencies, and international donor programs are increasingly including injectable therapies in HIV prevention and treatment protocols as part of global UNAIDS goals for ending the HIV epidemic.

The Growth in the HIV Injections Market Is Driven by Several Factors…

The growth in the HIV injections market is driven by several factors including pharmaceutical innovation in long-acting formulations, increased demand for adherence-friendly therapies, and global initiatives to improve ART access. Technologically, sustained-release injectable platforms and nanoparticle delivery systems are enabling extended therapeutic coverage and reducing dosing frequency. Regulatory approvals and clinical guideline updates are supporting market entry in high-income countries, while donor-led programs are accelerating pilot deployments in low-income regions.

From an end-use perspective, growing demand for PrEP among high-risk populations, improved treatment outcomes among non-adherent patients, and healthcare provider preference for simplified monitoring are propelling injectable adoption. As stigma, adherence fatigue, and global access challenges persist, HIV injections offer a compelling alternative to traditional oral regimens-one that aligns with the global effort to improve quality of life and viral suppression outcomes for all individuals living with or vulnerable to HIV.

SCOPE OF STUDY:

The report analyzes the HIV Injections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson (Janssen)
  • Lupin Limited
  • Mylan N.V. (Viatris Inc.)
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz (a Novartis division)
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • ViiV Healthcare
  • Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • HIV Injections - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Long-Acting Antiretrovirals Propels Demand for Injectable HIV Therapies
    • Rising Patient Preference for Reduced Dosing Frequency Strengthens Market for Monthly and Bi-Monthly Injections
    • FDA and EMA Approvals of Long-Acting Injectables Accelerate Clinical and Commercial Adoption
    • Growth in Pre-Exposure Prophylaxis (PrEP) Programs Fuels Uptake of Injectable HIV Prevention Solutions
    • Increased Adherence Challenges With Oral Therapies Drive Transition to Injectable Delivery Formats
    • Public Health Partnerships in Low-Income Regions Expand Access to Long-Acting HIV Injections
    • Pharmaceutical Innovation in Dual-Drug Injectable Combinations Enhances Viral Suppression Rates
    • Global HIV Elimination Targets Throw Spotlight on Scalable Injection-Based Solutions
    • Integration With Community Clinics and Mobile Health Units Increases Injection Reach in Rural Areas
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV Injections Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for HIV Injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Drugs Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for HIV Injections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for HIV Injections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for HIV Injections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Spain 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Russia 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for HIV Injections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for HIV Injections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for HIV Injections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Australia 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: India 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: South Korea 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for HIV Injections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for HIV Injections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for HIV Injections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Argentina 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Brazil 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Mexico 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for HIV Injections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for HIV Injections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for HIV Injections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Iran 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Israel 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UAE 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • HIV Injections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for HIV Injections by Distribution Channel - Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Africa 15-Year Perspective for HIV Injections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Drugs Stores & Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION